药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02617 药捷安康-B

休市中 06-26 16:08:11

9.100

-0.330

-3.50%

最高9.860	最低9.040	成交量1,197万
今开9.580	昨收9.430	日振幅8.70%
总市值37.13亿	流通市值28.48亿	总股本4.08亿
成交额1.12亿	换手率3.82%	流通股本3.13亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":9.1,"timestamp":1782461291004,"preClose":9.43,"halted":0,"volume":11965084,"delay":0,"changeRate":-0.034994697773064694,"floatShares":313000000,"shares":408000000,"eps":-0.76,"marketStatus":"休市中","change":-0.33,"latestTime":"06-26 16:08:11","open":9.58,"high":9.86,"low":9.04,"amount":112081677,"amplitude":0.086957,"askPrice":9.1,"askSize":9000,"bidPrice":9.09,"bidSize":14000,"shortable":3,"etf":0,"ttmEps":-0.803,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782696600000},"marketStatusCode":7,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":9.43,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"volumeRatio":0.6746371892655739,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617/wiki","defaultTab":"wiki","newsList":[{"id":"2646332831","title":"港股异动 | 药捷安康-B(02617.HK)再跌超3% 市值较高点蒸发超98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646332831","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646332831?lang=zh_cn&edition=full","pubTime":"2026-06-26 14:26","pubTimestamp":1782455167,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646266118","title":"270天，2700亿港元灰飞烟灭：药捷安康的“裸泳”时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2646266118","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646266118?lang=zh_cn&edition=full","pubTime":"2026-06-25 11:38","pubTimestamp":1782358712,"startTime":"0","endTime":"0","summary":"2026年6月23日，药捷安康-B（02617.HK）上市一周年，第二阶段限售股解禁3.82亿股（占总股本超90%），股价单日暴跌59.71%，收报11.25港元。6月24日，跌势未止，截至收盘，再跌11.11%至10港元。两个交易日累计跌幅超60%，总市值从解禁前约114亿港元缩水至约41亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606253782802976.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606253782802976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645866372","title":"港股异动 | 药捷安康-B(02617)盘中跌超4%创新低 总市值缩水至不足45亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645866372","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645866372?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:46","pubTimestamp":1782269175,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药捷安康-B继昨日大跌近60%后，今早盘中再跌超4%，触及10.51港元再创新低，总市值缩水至不足45亿港元。年初至今，药捷安康累计下跌已超过90%。消息面上，6月23日，药捷安康上市届满一年，迎来第二阶段解禁，本次解禁股份约3.82亿股，占总股本比例超90%，几乎实现全流通。财务报告显示，截至2025年底，药捷安康无商业化营收。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","BK1161","02617","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645083082","title":"药捷安康大跌60%：市值降至46亿港元 无收入却曾市值超千亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2645083082","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645083082?lang=zh_cn&edition=full","pubTime":"2026-06-23 23:22","pubTimestamp":1782228146,"startTime":"0","endTime":"0","summary":"港股有这样一家神奇的企业，无任何营收，却曾市值超过2000亿港元，如今，被打回原形，市值跌至不足50亿港元。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260623/6391785372985016268134583.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260623/6391785372985016268134583.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34120/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645837657","title":"3个月50倍大牛股“崩”了，今天暴跌近60%，2500亿市值只剩零头","url":"https://stock-news.laohu8.com/highlight/detail?id=2645837657","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645837657?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:30","pubTimestamp":1782225001,"startTime":"0","endTime":"0","summary":"2026年6月23日，港股18A创新药企药捷安康-B股价大跌，股价早盘大幅跳空低开后持续俯冲，最终收跌59.71%，每股报11.25港元，一举跌破13.15港元的IPO发行价，创下上市以来历史新低。这家股价曾经在三个月大涨超50倍的网红创新药企，市值已从最高2500亿港元跌至47亿港元，市值缩水98%。2026年6月22日，公司12个月大额限售股正式解禁，覆盖控股股东、全部上市前机构投资者，解禁股份体量是现有流通盘的数十倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fenghuang_stock","url":"https://finance.ifeng.com/c/8uCSNq902yo","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8uCSNq902yo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["IPOS","BK1161","02617","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645888324","title":"港股“子”曰 | 股价“脚踝斩”！药捷安康的“恐怖故事”没完没了","url":"https://stock-news.laohu8.com/highlight/detail?id=2645888324","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645888324?lang=zh_cn&edition=full","pubTime":"2026-06-23 14:55","pubTimestamp":1782197708,"startTime":"0","endTime":"0","summary":"今天，去年港股的超级“妖股”药捷安康再次崩盘，盘中股价暴跌超60%，今年以来累计跌幅近90%。其他很多股票，股价被“腰斩”的案例很多，但药捷安康却是遭遇了“脚踝斩”。刚好，今天是药捷安康上市满一周年的日子，回顾这一年来该公司的表现，可谓“恐怖故事”没完没了。刚上市时，药捷安康发行价仅为13.15港元，上市之后股价也只有20港元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606233779657671.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606233779657671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","02617","BK1161","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645500035","title":"半年内三次折价配售叠加大股东解禁，药捷安康-B(02617)股价单日暴跌约60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645500035","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645500035?lang=zh_cn&edition=full","pubTime":"2026-06-23 13:06","pubTimestamp":1782191167,"startTime":"0","endTime":"0","summary":"6月23日， 药捷安康-B上市届满一年迎来第二阶段解禁。深股通资金坚决且不计成本地抛售筹码，成为药捷安康股价失去支撑并自由下坠的直接诱因。之后药捷安康虽在去年10月16日至11月6日迎来一波可观的股价反弹，其中10月16日公司股价单日创下46.34%的股价涨幅。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645004370","title":"港股速报 | 港股小幅高开 药捷安康暴跌超50% 创上市以来新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2645004370","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645004370?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:19","pubTimestamp":1782181189,"startTime":"0","endTime":"0","summary":"今日（6月23日），港股市场小幅高开。早间开盘，恒生指数报23800.02点，上涨31.50点，涨幅0.13%；恒生科技指数开盘报4551.45点，上涨2.04点，涨幅0.04%。今日港股焦点在新股，两只新股上市，一只大涨，一只却大幅破发。首先，星源材质（HK06067）早盘一度涨近50%，截至发稿涨超36%。星源材质是一家具有竞争力的锂离子电池隔膜制造商。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606233779318075.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606233779318075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK1161","IPOS","VXUS","02617","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135156996","title":"港股直击 | 「妖股」药捷安康放量急泻逾50%，上市届满一年迎来解禁，年内已三次配股集资","url":"https://stock-news.laohu8.com/highlight/detail?id=1135156996","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135156996?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:41","pubTimestamp":1782178877,"startTime":"0","endTime":"0","summary":"「妖股」药捷安康放量急泻逾50%，成交1.2亿港元。6 月 12 日，港股上市公司药捷安康宣布，孙德龙被任命为公司的首席运营官，自 2026 年 6 月 12 日起生效，在该岗位上，孙德龙将负责药捷安康商业化运营全部事务。据公开信息，孙德龙毕业于沈阳药科大学药学专业，在生物医药行业拥有逾二十年的丰富经验，其曾于于2006 年 7 月至 2021 年 12 月期间，任职于江苏先声药业有限公司，曾先后担任东北大区经理、全国销售总监、集团运行总监及北京分公司总经理，其中，2017 年至 2021 年 12 月期间担任集团运行总监。","market":"hk","thumbnail":"https://static.tigerbbs.com/3299f0aa430f44d45729a266d0f7b350","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3299f0aa430f44d45729a266d0f7b350"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"「妖股」药捷安康放量急泻逾50%，上市届满一年迎来解禁，年内已三次配股集资","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645001585","title":"港股药捷安康-B跌超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645001585","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645001585?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:35","pubTimestamp":1782178529,"startTime":"0","endTime":"0","summary":"港股药捷安康-B跌超50%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606233779040046.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606233779040046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["VXUS","BK1161","02617","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645094238","title":"药捷安康任命孙德龙为COO 负责公司商业化运营事务","url":"https://stock-news.laohu8.com/highlight/detail?id=2645094238","media":"雷递网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645094238?lang=zh_cn&edition=full","pubTime":"2026-06-21 13:21","pubTimestamp":1782019319,"startTime":"0","endTime":"0","summary":"药捷安康（南京）科技股份有限公司（简称：“药捷安康”，股份代号：2617）日前宣布，任命孙德龙为公司COO，孙德龙将负责公司商业化运营全部事务。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260621/6391764491648328314520918.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260621/6391764491648328314520918.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34094/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["COO","LU2272731600.USD","LU1992135399.USD","BK1161","BK4198","BK4588","LU1992135472.HKD","BK4585","02617","LU2211815571.USD","LU2272731782.SGD","GB00BDT5M118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083744","title":"药捷安康-B(02617)：冯维波获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083744","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644083744?lang=zh_cn&edition=full","pubTime":"2026-06-18 20:26","pubTimestamp":1781785586,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)发布公告，经股东周年大会批准，冯维波先生已获委任为第二届董事会独立非执行董事，自2026年6月18日起生效，直至第二届董事会任期届满之日止。同时，冯维波先生已获委任为董事会薪酬与考核委员会主席，以及董事会审计委员会及董事会提名委员会成员。此外，郑哲兰女士于股东周年大会结束后不再担任公司独立非执行董事，同时不再担任薪酬与考核委员会主席以及审计委员会及提名委员会成员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642329566","title":"药捷安康-B(02617)：孙德龙获委任为首席运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2642329566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642329566?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:22","pubTimestamp":1781270572,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)发布公告，孙德龙先生已获公司董事会委任为公司的首席运营官，自2026年6月12日起生效。于该职位，孙先生将负责公司商业化运营全部事务。孙先生在生物医药行业拥有逾二十年的丰富经验，具备从一线药品营销及学术推广至企业全面运营的全链条管理能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641177443","title":"药捷安康-B现涨逾9% 近日完成384万股新H股配售净筹约1.52亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641177443","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641177443?lang=zh_cn&edition=full","pubTime":"2026-06-08 10:06","pubTimestamp":1780884360,"startTime":"0","endTime":"0","summary":"　　药捷安康-B盘中涨超14%，截至发稿，股价上涨8.87%，现报34.38港元。配售代理成功以每股配售股份40.83港元的价格向不少于六名承配人配售合共384万股配售股份。　　此次配售事项所得款项总额约为1.57亿港元，扣除配售佣金及其他相关成本后的净额约为1.52亿港元，净发行价约为每股配售股份39.66港元。公司计划将净额的约90%用于核心产品Tinengotinib的新适应症开发，其余约10%用于运营资金及一般企业用途。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-06-08/doc-iniasfpw7213075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641776501","title":"港股异动 | 药捷安康-B(02617)涨超4% 替恩戈替尼单药治疗晚期胆管癌关键II期临床数据于2026 ASCO年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2641776501","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641776501?lang=zh_cn&edition=full","pubTime":"2026-06-08 09:48","pubTimestamp":1780883327,"startTime":"0","endTime":"0","summary":"消息面上，近日，药捷安康-B发布公告，公司在芝加哥举办的2026年美国临床肿瘤学会上以壁报形式公布了核心产品替恩戈替尼单药治疗既往FGFR抑制剂经治的中国晚期胆管癌患者的最新研究成果。FGFR抑制剂在治疗化疗难治性、携带FGFR2变异的胆管癌方面具有明确的作用。本次ASCO大会上，公开了替恩戈替尼在携带FGFR2变异、既往接受过一种FGFR抑制剂治疗后发生疾病进展的胆管癌患者中的疗效与安全性数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","BK1161","02617","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142196069","title":"异动解读｜药捷安康-B盘中下跌5.41%，ASCO大会公布核心产品临床数据后股价承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1142196069","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142196069?lang=zh_cn&edition=full","pubTime":"2026-06-05 15:20","pubTimestamp":1780644021,"startTime":"0","endTime":"0","summary":"6月5日，药捷安康-B盘中下跌5.41%，报32.14港元，成交额7285.01万港元。消息面上，公司近日在ASCO大会以壁报形式公布了核心产品替恩戈替尼单药治疗既往FGFR抑制剂经治的晚期胆管癌患者关键II期临床数据，截至数据截止日共50例患者入组。此外，公司此前已获纳入香港交易所科技100指数，将于6月15日起生效。药捷安康是一家专注于肿瘤、炎症及心脏代谢疾病小分子创新疗法的生物制药公司，核心产品替恩戈替尼为处于注册临床阶段的MTK抑制剂。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174158425","title":"药捷安康-B更新5月股份变动月报：H股增发3,836,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1174158425","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174158425?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:43","pubTimestamp":1780396998,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年6月2日发布了截至2026年5月31日的股份变动月报表，披露了公司在2026年5月的股本变动情况。其中，普通股H股由2026年4月底的308,851,673股增加至312,687,673股，增发数量为3,836,000股。根据公告，本月公司完成了以每股港币40.83元的价格配售（或认购）新H股3,836,000股。截至本月末，公司股本总数较上月有所增加，最新已发行股份总数为312,687,673股H股和95,230,960股非上市普通股，合计407,918,633股。据公告内容，月报由联席公司秘书黄荻代表签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639253600","title":"药捷安康-B(02617)：在2026年美国临床肿瘤学会(ASCO)公布替恩戈替尼单药治疗晚期胆管癌关键II期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2639253600","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639253600?lang=zh_cn&edition=full","pubTime":"2026-05-31 18:08","pubTimestamp":1780222112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，公司在芝加哥举办的2026年美国临床肿瘤学会上以壁报形式公布了核心产品替恩戈替尼单药治疗既往FGFR抑制剂经治的中国晚期胆管癌患者的最新研究成果。本次ASCO大会上，公开了替恩戈替尼在携带FGFR2变异、既往接受过一种FGFR抑制剂治疗后发生疾病进展的胆管癌患者中的疗效与安全性数据。截至2025年12月27日，共有50例晚期胆管癌患者入组并接受了替恩戈替尼单药治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B(02617)：在2026年美国临床肿瘤学会(ASCO)公布替恩戈替尼单药治疗晚期胆管癌关键II期临床数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639243666","title":"香港交易所科技100指数半年度调整：调入滴普科技(01384)等7只科技股 剔除7只成分股","url":"https://stock-news.laohu8.com/highlight/detail?id=2639243666","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639243666?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:06","pubTimestamp":1780052772,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月29日，香港交易所宣布，宣布香港交易所科技100指数的半年度指数调整结果，调入滴普科技(01384)、汇聚科技(01729)、禾赛科技(02525)、极智嘉(02590)、药捷安康(02617)、曹操出行(02643)、长飞光纤光缆(06869)等7只科技股，同时剔除7只成分股。成分股调整将于2026年6月12日(星期五)收市后实施，并于2026年6月15日(星期一)起生效。香港交易所科技100指数是一只宽基指数，追踪100只在香港上市且可在港股通下交易的科技股表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0651947912.USD","LU0819123356.HKD","LU0561508036.HKD","SG9999002463.SGD","LU0348814723.USD","IE00BZ08YR35.GBP","00388","LU0196878994.USD","LU0955648018.USD","SGXZ90724238.SGD","LU0096374516.USD","02617","LU0605514214.HKD","LU0067412154.USD","LU0082770016.USD","LU0918141887.USD","LU0140636845.USD","LU1023057109.AUD","LU0417516738.SGD","LU0594300179.USD","LU0819121731.USD","LU0577902611.USD","IE0003795394.USD","LU0577902454.USD","LU0320764599.SGD","LU0630378429.USD","LU0164880469.USD","SG9999002562.SGD","LU0048580855.USD","BK1255","LU1655091459.SGD","LU0274383008.USD","LU0197773160.USD","LU0540923850.HKD","LU1282648689.USD","LU0307460666.USD","LU0577902298.EUR","01729","BK1117","LU0955669360.SGD","LU1044875133.USD","LU0164939612.USD","LU0348825331.USD","LU1807302812.USD","LU0165289439.USD","LU0762540952.USD","LU0072462343.USD","LU0588546209.SGD","LU0048597586.USD","IE00BZ08YT58.USD","LU0784639295.USD","LU0197773673.USD","BK1610","LU0348816934.USD","LU1282649067.USD","LU0061477393.USD","LU0516422952.EUR","LU0348766576.USD","LU2226246903.HKD","SG9999006597.SGD","LU0261947096.USD","LU0314109678.HKD","SG9999001846.SGD","LU2257852520.SGD","LU1044876610.USD","LU0516422440.USD","LU1282649810.SGD","LU1105468828.SGD","LU0831103253.SGD","LU0594300419.USD","BK1589","LU0873338254.USD","BK1149","LU0072913022.USD","LU0106959298.USD","LU1044874839.SGD","LU0886674414.USD","LU0348827113.USD","IE00B3T34201.USD","LU0384037296.USD","LU0577902371.SGD","LU1048596156.SGD","LU1993786604.SGD","LU0348767384.USD","LU0797268264.HKD","LU1734074674.USD","LU0082770016.SGD","LU0052750758.USD","LU2039709279.SGD","LU0011963245.USD","HSAI","LU2449936058.SGD","BK1506","BK1523","LU1481107354.HKD","BK1183","LU0898667661.SGD","LU0084288322.USD","LU1642822792.SGD","LU0516423174.USD","LU0762542818.HKD","LU0210527791.USD","LU0211977185.USD","LU0955623706.USD","LU0630378692.HKD","LU1130305938.SGD","BK1131","BK1161","02643","LU0501845795.SGD","LU0359202008.SGD","LU0370786039.SGD","IE0003851619.USD","LU0516423091.SGD","BK1144","LU1051768304.USD","LU1328277881.USD","LU1048588211.SGD","SG9999001093.SGD","LU1366334651.USD","LU0651946864.USD","LU1981816686.USD","LU1813983027.USD","LU0762541174.USD","80388","LU0831093199.SGD","LU1051769294.HKD","SG9999004220.SGD","LU0708995583.HKD","LU1242518931.SGD","LU0577902538.SGD","02525","HKXCY","LU0516422366.SGD","LU1366334578.USD","LU0117841782.USD","LU0607220059.USD","06869","BK1116","LU0359201885.HKD","LU1242518857.USD","LU0648948544.HKD","LU1831875114.USD","LU0149534421.HKD","SG9999001051.SGD","LU0327786744.USD","LU0856984785.SGD","LU0456846285.SGD","LU1226287529.USD","BK1521","LU0043850808.USD","LU0417516902.SGD","LU1282649141.HKD","LU0572944931.SGD","LU0359201612.USD","LU0650527681.SGD","LU0918141705.HKD","LU1515016050.SGD","LU0791591158.USD","IE00BKZH1Z71.USD","LU0169518387.USD","01384","LU0251144936.SGD","LU0348735423.USD","LU1211504680.USD","HK0000151867.HKD","LU0117844026.USD","LU0634319403.HKD","LU0488056044.USD","HK0000107257.USD","IE00BZ08YS42.EUR","LU0620787316.HKD","LU0821914370.USD","LU0149721374.USD","02590","LU0979878070.USD","601869","LU1504937902.USD","LU0791590937.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143184711","title":"药捷安康-B：配售3,836,000股H股，涉资约1.57亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143184711","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143184711?lang=zh_cn&edition=full","pubTime":"2026-05-27 21:02","pubTimestamp":1779886929,"startTime":"0","endTime":"0","summary":"药捷安康-B（股票代码：02617）于2026年5月27日发布公告，宣布通过配售方式发行3,836,000股H股。该次发行基于公司于2025年8月4日召开的股东周年大会授权。\n本次配售股份占发行前公司已发行股本约1.24%，每股价格为港币40.83元，合计涉资约1.57亿港元。配售完成后，公司已发行股本由308,851,673股增至312,687,673股，库存股数量维持为零。\n公司同时在公告中确认，已遵守香港联合交易所有限公司证券上市规则及相关法律法规，并按照董事会的正式授权推进各项程序。公告由董事长兼首席执行官吴永谦先生签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B：配售3,836,000股H股，涉资约1.57亿港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":-0.6784},{"period":"1month","weight":-0.7649},{"period":"3month","weight":-0.8698},{"period":"6month","weight":-0.9301},{"period":"1year","weight":-0.654},{"period":"ytd","weight":-0.9208}],"compareEarnings":[{"period":"1week","weight":-0.0524},{"period":"1month","weight":-0.1049},{"period":"3month","weight":-0.0914},{"period":"6month","weight":-0.1219},{"period":"1year","weight":-0.068},{"period":"ytd","weight":-0.1154}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康（南京）科技股份有限公司是一家从事生物制药的中国公司，主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的MTK抑制剂，适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括TT-00973（针对 AXL）、TT-01488（用于血液系统恶性肿瘤）、TT-01688（用于炎症性疾病）和 TT-00920（用于慢性心力衰竭）。这些产品能够对多种癌症类型（包括前列腺癌、肝癌、乳腺癌和BTC）产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和Pan-FGFR实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药捷安康-B,02617,药捷安康-B股票,药捷安康-B股票老虎,药捷安康-B股票老虎国际,药捷安康-B行情,药捷安康-B股票行情,药捷安康-B股价,药捷安康-B股市,药捷安康-B股票价格,药捷安康-B股票交易,药捷安康-B股票购买,药捷安康-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}